Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Human Cancer Immunology and Cancer Vaccine Development

NY-ESO-1 protein-based cancer vaccines: the Melbourne experience

Ian D. Davis, Weisan Chen, Max Schnurr, Wendie Hopkins, Lena Miloradovic, Lloyd J. Old, Eugene Maraskovsky and Jonathan S. Cebon
Ian D. Davis
1Ludwig Institute for Cancer Research, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weisan Chen
1Ludwig Institute for Cancer Research, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Max Schnurr
1Ludwig Institute for Cancer Research, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendie Hopkins
1Ludwig Institute for Cancer Research, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lena Miloradovic
2CSL Limited, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lloyd J. Old
3Ludwig Institute for Cancer Research, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugene Maraskovsky
1Ludwig Institute for Cancer Research, Melbourne, Australia
2CSL Limited, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan S. Cebon
1Ludwig Institute for Cancer Research, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2005
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

NY-ESO-1 is a "cancer-testis" (CT) antigen found in a wide variety of malignancies, including 35-45% of melanomas (1, 2). Expression of NY-ESO-1 by tumors commonly leads to spontaneous antibody and T-cell responses. Previous clinical trials involving HLA-A2-restricted NY-ESO-1 peptides have shown that these can be administered safely, generate T-cell responses, and may have clinical benefit (3). However, such approaches are restricted to HLA-A2 positive patients only and rely on the assumption that T-cell responses to this epitope are the most relevant. The use of full-length recombinant protein allows all possible relevant epitopes to be available for both HLA class I- and II-restricted responses.

Previous studies have shown that NY-ESO-1 formulated with specific antibodies as immune complexes (NY-ESO-1/IC) leads to enhanced uptake and processing by DCs (4). We were interested in comparing these functions when full length, recombinant NY-ESO-1 was formulated with ISCOMATRIX™ adjuvant (CSL Limited), a saponin-based adjuvant that has been shown to promote cellular and humoral immune responses in NY-ESO-1 pre-clinical models (5). The mode of antigen delivery was found to be a determining factor for cytosolic proteolysis by DC. NY-ESO-1/IC targeted a slow, proteasome-dependent cross-presentation pathway, whereas NY-ESO-1+ ISCOMATRIX™ adjuvant (NY-ESO-1/IMX) targeted a fast, proteasome-independent pathway. Both cross-presentation pathways resulted in a long-lived T cell stimulatory capacity, which was maintained for several days longer than for DCs pulsed with peptide. This may provide DCs with ample opportunity for sensitizing tumor-specific T cells against a broad array of tumor antigen epitopes in lymph nodes and thus has important implications for vaccine design and immunization strategies.

We performed a clinical trial (LUD99-008) in collaboration with CSL Limited, using NY-ESO-1/IMX. The protein was synthesized at CSL and purified at the Ludwig Institute Biological Production Facility in Melbourne. Forty-six evaluable patients with resected NY-ESO-1 positive tumors received three doses of NY-ESO-1/IMX intramuscularly at monthly intervals (6). The vaccine was well tolerated. We observed high titer antibody responses, strong DTH reactions, and circulating CD8+ and CD4+ T cells specific for a broad range of NY-ESO-1 epitopes, including known and previously unknown epitopes (6, 7). In an unplanned analysis, vaccinated patients appeared to have superior clinical outcomes to those treated with placebo or protein alone.

These observations have led to the initiation of several further clinical trials. In trial LUD2002-013, patients with advanced malignant melanoma whose tumors express NY-ESO-1 are being treated with NY-ESO-1/IMX. The objectives of this ongoing study are to determine in this patient population with advanced disease whether NY-ESO-1/IMX has anticancer activity, to study the immune responses elicited by vaccination, and to determine the safety of NY-ESO-1/IMX. This trial is currently accruing and a total of 25 patients is planned. Trial LUD2003-009, due to commence late 2004 or early 2005, is a randomized phase II trial in which high risk melanoma patients with resected stage III or IV disease will be treated with NY-ESO-1/IMX or with ISCOMATRIX™ adjuvant alone. This study will determine the relapse-free survival at 18 months using these approaches and will provide data to allow power calculations for a future randomized phase III study that will determine whether NY-ESO-1/IMX vaccination can prevent or delay relapse in this population. A critical aspect of this trial will be a rapid, simple and generalizable assay to detect patients with immune responses.

Based on the data from our previous studies and the observations concerning antigen processing pathways in DCs using NY-ESO-1/IMX, we have initiated trial LUD2003-013. This is a pilot study in which autologous peripheral blood DCs will be harvested, pulsed ex vivo with NY-ESO-1/IMX, and administered back to patients with resected NY-ESO-1 positive cancer. The nature of the immune responses elicited will be determined and qualitative comparisons with the previous LUD99-008 trial will be made.

Multivalent vaccines are likely to be necessary ultimately in order for vaccines using defined antigens to be more generally applicable. Other antigens and more simple methods of antigen delivery will need to be investigated. Future work in this program will examine the implications of different methods of antigen delivery to antigen-presenting cells both in vivo and ex vivo, and also whether the rules for NY-ESO-1 also apply to other antigens. This work will only succeed if appropriate, feasible and relevant immunological and clinical endpoints are included in the study designs and if there is close integration between the laboratory and the clinic.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

 

  • Copyright © 2005 by Ian D. Davis

References

  1. 1.
    1. Scanlan MJ,
    2. Simpson AJ,
    3. Old LJ
    . The cancer/testis genes: Review, standardization, and commentary. Cancer Immun 2004;4:1–1.pmid:14738373
    OpenUrlAbstract/FREE Full Text
  2. 2.
    1. Vaughan HA,
    2. Svobodova S,
    3. MacGregor D,
    4. et al.
    Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer testis (CT) antigens NY-ESO-1 and LAGE-1. Clin Cancer Res. In press. 
  3. 3.
    1. Jäger E,
    2. Gnjatic S,
    3. Nagata Y,
    4. Stockert E,
    5. Jäger D,
    6. Karbach J,
    7. Neumann A,
    8. Rieckenberg J,
    9. Chen YT,
    10. Ritter G,
    11. Hoffman E,
    12. Arand M,
    13. Old LJ,
    14. Knuth A
    . Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000;97:12198–203.pmid:11027314
    OpenUrlAbstract/FREE Full Text
  4. 4.
    1. Nagata Y,
    2. Ono S,
    3. Matsuo M,
    4. Gnjatic S,
    5. Valmori D,
    6. Ritter G,
    7. Garrett W,
    8. Old LJ,
    9. Mellman I
    . Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci U S A 2002;99:10629–34.pmid:12138174
    OpenUrlAbstract/FREE Full Text
  5. 5.
    1. Maraskovsky E,
    2. Sjolander S,
    3. Drane DP,
    4. Schnurr M,
    5. Le TT,
    6. Mateo L,
    7. Luft T,
    8. Masterman KA,
    9. Tai TY,
    10. Chen Q,
    11. Green S,
    12. Sjolander A,
    13. Pearse MJ,
    14. Lemonnier FA,
    15. Chen W,
    16. Cebon J,
    17. Suhrbier A
    . NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res 2004;10:2879–90.pmid:15102697
    OpenUrlAbstract/FREE Full Text
  6. 6.
    1. Davis ID,
    2. Chen W,
    3. Jackson H,
    4. Parente P,
    5. Shackleton M,
    6. Hopkins W,
    7. Chen Q,
    8. Dimopoulos N,
    9. Luke T,
    10. Murphy R,
    11. Scott AM,
    12. Maraskovsky E,
    13. McArthur G,
    14. MacGregor D,
    15. Sturrock S,
    16. Tai TY,
    17. Green S,
    18. Cuthbertson A,
    19. Maher D,
    20. Miloradovic L,
    21. Mitchell SV,
    22. Ritter G,
    23. Jungbluth AA,
    24. Chen YT,
    25. Gnjatic S,
    26. Hoffman EW,
    27. Old LJ,
    28. Cebon JS
    . Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T-cell responses in humans. Proc Natl Acad Sci U S A 2004;101:10697–702.pmid:15252201
    OpenUrlAbstract/FREE Full Text
  7. 7.
    1. Chen Q,
    2. Jackson H,
    3. Parente P,
    4. Luke T,
    5. Rizkalla M,
    6. Tai TY,
    7. Zhu HC,
    8. Mifsud NA,
    9. Dimopoulos N,
    10. Masterman KA,
    11. Hopkins W,
    12. Goldie H,
    13. Maraskovsky E,
    14. Green S,
    15. Miloradovic L,
    16. McCluskey J,
    17. Old LJ,
    18. Davis ID,
    19. Cebon J,
    20. Chen W
    . Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A 2004;101:9363–8.pmid:15197261
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Cancer Immunity Archive: 5 (Suppl 1)
January 2005
Volume 5, Issue Suppl 1
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
NY-ESO-1 protein-based cancer vaccines: the Melbourne experience
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
NY-ESO-1 protein-based cancer vaccines: the Melbourne experience
Ian D. Davis, Weisan Chen, Max Schnurr, Wendie Hopkins, Lena Miloradovic, Lloyd J. Old, Eugene Maraskovsky and Jonathan S. Cebon
Cancer Immun January 1 2005 (5) (Suppl 1) 13;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
NY-ESO-1 protein-based cancer vaccines: the Melbourne experience
Ian D. Davis, Weisan Chen, Max Schnurr, Wendie Hopkins, Lena Miloradovic, Lloyd J. Old, Eugene Maraskovsky and Jonathan S. Cebon
Cancer Immun January 1 2005 (5) (Suppl 1) 13;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Melanoma peptide vaccines: multipeptide approaches for targeting cytotoxic and helper T cells
  • Lessons from a pilot clinical trial of vaccine therapy with an NY-ESO-1 peptide of dual MHC class I and II specificities in ovarian cancer
  • Immunity to SOX group B and ZIC2 antigens: novel neuro-ectodermal targets and clinical indicators in small cell lung cancer
Show more Human Cancer Immunology and Cancer Vaccine Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement